Inspira Technologies Enhances Leadership with Strategic Appointments

Inspira Technologies Strengthens Leadership Team
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) has made significant strides in its leadership structure, appointing Mike Hershkovitz as Vice President of Global Sales and Sivan Matza as a new board member. This strategic move is aimed at bolstering the company's global commercialization efforts and enhancing its governance framework. With these appointments, Inspira is poised to accelerate its mission of delivering innovative life-support and diagnostic technologies to healthcare markets worldwide.
Key Appointments Driving Growth
Meet Mike Hershkovitz
Mike Hershkovitz joins Inspira from a rich background, having spent nearly 20 years leading teams in both U.S. and international healthcare sectors. His expertise encompasses senior roles in major medical technology companies, including a notable tenure at Johnson & Johnson. As Vice President of Global Sales, Mike aims to refine Inspira's sales strategies and drive the adoption of its innovative products in hospitals globally. His deep understanding of the med-tech landscape is expected to be a cornerstone in expanding Inspira's market reach.
Introducing Sivan Matza
Sivan Matza comes on board as an independent director, bringing with her a wealth of experience from her role at a prominent international investment management firm. She has overseen billions in assets and has cultivated significant proficiency in finance, regulation, and accounting. Her appointment is seen as a vital enhancement to Inspira’s governance as it navigates its commercial expansion. Sivan is also set to contribute to the board’s compensation, audit, and financial statement examination committees, ensuring robust oversight and strategic direction.
CEO's Vision for Inspira's Future
Dagi Ben-Noon, the CEO of Inspira Technologies, expressed enthusiasm about these new appointments, viewing them as a strategic advantage for the company. He stated that both Sivan and Mike would substantially augment Inspira's capabilities as it strives to grow its operations. With Sivan's financial and regulatory experience and Mike's sales acumen, Inspira is well-positioned to enhance its product offerings and foster greater technology adoption in global markets. This dynamic duo is expected to be key players in Inspira's next growth phase and overall stakeholder service.
Acknowledging Contributions
As Inspira Technologies welcomes its new leaders, the company also takes a moment to acknowledge Limor Rosen's contributions as a board member. On her departure, Tal Parnes, the chairman of the board, thanked her for her dedication to Inspira’s vision and wished her well in her future endeavors. This transition symbolizes Inspira's ongoing commitment to assembling the best talent to guide its trajectory.
About Inspira Technologies
Inspira Technologies is revolutionizing the medical device landscape, focusing on advanced respiratory support and real-time blood monitoring technologies. Their flagship product, the INSPIRA™ ART100 system, is already FDA-approved for cardiopulmonary bypass and contributes to ECMO procedures outside the United States. Furthermore, they are currently developing the INSPIRA ART500 system, which aims to optimize oxygen delivery in patients who remain awake—marking a significant advancement in patient care.
In addition, the company is advancing HYLA™, a novel blood sensor platform designed for continuous, non-invasive patient monitoring. With many cleared devices and a growing intellectual property portfolio, Inspira Technologies stands out as a key player in the life-support and MedTech sectors. Its organizational shifts are reflective of a broader alignment with enduring industry trends, such as consolidation and cross-sector collaboration.
Frequently Asked Questions
Who is the new Vice President of Global Sales at Inspira Technologies?
The new Vice President of Global Sales is Mike Hershkovitz, who has extensive experience in the med-tech industry.
What role does Sivan Matza hold at Inspira Technologies?
Sivan Matza has been appointed as an independent director on the board, bringing her expertise in finance and regulation.
What is the focus of Inspira Technologies?
Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions for healthcare.
What innovations is Inspira Technologies currently developing?
Inspira Technologies is developing the INSPIRA ART500 system for improved patient oxygenation during awake procedures, along with the HYLA™ blood sensor platform.
How does the company recognize the contributions of departing board members?
The company publicly acknowledges and appreciates the efforts of departing board members, as seen in the farewell to Limor Rosen.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.